Top-Rated StocksTop-RatedNASDAQ:PCRX Pacira BioSciences (PCRX) Stock Price, News & Analysis → This military-backed stock “owns” AI market (From Porter & Company) (Ad) Free PCRX Stock Alerts $30.33 -0.13 (-0.43%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$30.21▼$30.9950-Day Range$25.50▼$31.5152-Week Range$25.33▼$41.65Volume717,143 shsAverage Volume1.02 million shsMarket Capitalization$1.41 billionP/E Ratio21.21Dividend YieldN/APrice Target$47.40 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Pacira BioSciences alerts: Email Address Pacira BioSciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside56.3% Upside$47.40 Price TargetShort InterestBearish12.98% of Shares Sold ShortDividend StrengthN/ASustainability-1.89Upright™ Environmental ScoreNews Sentiment0.03Based on 8 Articles This WeekInsider TradingSelling Shares$2.79 M Sold Last QuarterProj. Earnings Growth34.27%From $2.13 to $2.86 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.60 out of 5 starsMedical Sector78th out of 928 stocksPharmaceutical Preparations Industry28th out of 437 stocks 3.5 Analyst's Opinion Consensus RatingPacira BioSciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePacira BioSciences has only been the subject of 4 research reports in the past 90 days.Read more about Pacira BioSciences' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted12.98% of the outstanding shares of Pacira BioSciences have been sold short.Short Interest Ratio / Days to CoverPacira BioSciences has a short interest ratio ("days to cover") of 9.4.Change versus previous monthShort interest in Pacira BioSciences has recently increased by 67.78%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPacira BioSciences does not currently pay a dividend.Dividend GrowthPacira BioSciences does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePacira BioSciences has received a 52.23% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Bupivacaine", "Cryotherapy devices", and "Drug delivery devices" products. See details.Environmental SustainabilityThe Environmental Impact score for Pacira BioSciences is -1.89. Previous Next 2.2 News and Social Media Coverage News SentimentPacira BioSciences has a news sentiment score of 0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Pacira BioSciences this week, compared to 3 articles on an average week.Search Interest6 people have searched for PCRX on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Pacira BioSciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pacira BioSciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,785,628.00 in company stock.Percentage Held by InsidersOnly 6.40% of the stock of Pacira BioSciences is held by insiders.Percentage Held by Institutions99.73% of the stock of Pacira BioSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Pacira BioSciences' insider trading history. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Pacira BioSciences are expected to grow by 34.27% in the coming year, from $2.13 to $2.86 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pacira BioSciences is 21.21, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 134.63.Price to Earnings Ratio vs. SectorThe P/E ratio of Pacira BioSciences is 21.21, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 158.46.Price to Book Value per Share RatioPacira BioSciences has a P/B Ratio of 1.58. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Pacira BioSciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Freeport SocietyBiden Nomination CANCELED?The Hill just published that Joe Biden has received enough delegates to…“clinch the Democratic presidential nomination and all but guaranteeing he will face off against former President Trump again in November.” Why is he all BUT guaranteed the Democratic nomination, in their words?I believe I have the terrifying answer right here. About Pacira BioSciences Stock (NASDAQ:PCRX)Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.Read More PCRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PCRX Stock News HeadlinesJune 1 at 1:44 AM | americanbankingnews.comQ3 2024 Earnings Forecast for Pacira BioSciences, Inc. Issued By Zacks Research (NASDAQ:PCRX)May 30 at 8:00 AM | globenewswire.comPacira BioSciences to Participate in Fireside Chat at the 2024 Jefferies Global Healthcare ConferenceMay 25, 2024 | finance.yahoo.comPacira BioSciences, Inc. (PCRX)May 10, 2024 | markets.businessinsider.comPacira BioSciences Announces Pricing Of $250 Mln Of Convertible Senior Notes, Due 2029May 10, 2024 | finance.yahoo.comEarnings Miss: Pacira BioSciences, Inc. Missed EPS By 17% And Analysts Are Revising Their ForecastsMay 10, 2024 | globenewswire.comPacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029May 8, 2024 | globenewswire.comPacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior NotesMay 8, 2024 | finance.yahoo.comPacira BioSciences, Inc. (NASDAQ:PCRX) Q1 2024 Earnings Call TranscriptMay 8, 2024 | finance.yahoo.comPacira BioSciences Inc (PCRX) (Q1 2024) Earnings Call Transcript Highlights: Strategic Growth ...May 7, 2024 | investorplace.comPCRX Stock Earnings: Pacira BioSciences Meets EPS, Beats Revenue for Q1 2024May 7, 2024 | seekingalpha.comPacira BioSciences, Inc. 2024 Q1 - Results - Earnings Call PresentationMay 7, 2024 | msn.comPacira BioSciences Non-GAAP EPS of $0.62, revenue of $167.11MMay 7, 2024 | finance.yahoo.comPacira BioSciences Reports Q1 2024 Results: Aligns with EPS Projections and Announces $150 ...May 7, 2024 | globenewswire.comPacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase programMay 7, 2024 | finance.yahoo.comPacira BioSciences to Participate in Fireside Chat at the 2024 RBC Capital Markets Global Healthcare ConferenceApril 30, 2024 | globenewswire.comPacira to Report First Quarter 2024 Financial Results on Tuesday May 7, 2024April 17, 2024 | nasdaq.comOversold Conditions For Pacira BioSciences (PCRX)April 11, 2024 | finance.yahoo.comPacira BioSciences (NASDAQ:PCRX) stock falls 4.1% in past week as three-year earnings and shareholder returns continue downward trendApril 9, 2024 | markets.businessinsider.comUnderstanding Key Factors Behind Pacira Pharmaceuticals’ Analyst RatingApril 6, 2024 | nasdaq.comCommit To Purchase Pacira BioSciences At $15, Earn 12.5% Annualized Using OptionsApril 2, 2024 | globenewswire.comPacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare ConferenceMarch 16, 2024 | finance.yahoo.comPCRX Apr 2024 22.500 putMarch 13, 2024 | marketwatch.comPacira's PCRX-201 Gets FDA RMAT Designation in Knee OsteoarthritisMarch 13, 2024 | markets.businessinsider.comPacira BioSciences Receives RMAT Designation For Gene Therapy Product Candidate In OsteoarthritisMarch 13, 2024 | globenewswire.comPacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the KneeSee More Headlines Receive PCRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pacira BioSciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today6/01/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:PCRX CUSIP69512710 CIK1396814 Webwww.pacira.com Phone(813) 553-6680Fax302-655-5049Employees711Year FoundedN/APrice Target and Rating Average Stock Price Target$47.40 High Stock Price Target$57.00 Low Stock Price Target$38.00 Potential Upside/Downside+56.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)$1.43 Trailing P/E Ratio21.21 Forward P/E Ratio14.24 P/E GrowthN/ANet Income$41.96 million Net Margins10.34% Pretax Margin14.93% Return on Equity12.98% Return on Assets7.08% Debt Debt-to-Equity Ratio0.57 Current Ratio5.81 Quick Ratio4.78 Sales & Book Value Annual Sales$674.98 million Price / Sales2.09 Cash Flow$3.94 per share Price / Cash Flow7.70 Book Value$19.17 per share Price / Book1.58Miscellaneous Outstanding Shares46,550,000Free Float43,567,000Market Cap$1.41 billion OptionableOptionable Beta0.77 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Charles A. Reinhart III (Age 63)C.P.A., M.B.A., Chief Financial Officer Comp: $780.58kMr. Daryl Gaugler (Age 62)Chief Operating Officer Comp: $778.77kMs. Kristen Williams J.D. (Age 50)Chief Administrative Officer & Secretary Comp: $799.63kMr. Anthony Molloy III (Age 50)Esq., Chief Legal & Compliance Officer Comp: $581.41kMr. David M. Stack (Age 74)Advisor Comp: $1.54MMr. Frank D. Lee (Age 56)CEO & Director Ms. Lauren Bullaro Riker (Age 45)Principal Accounting Officer & Senior VP of Finance Comp: $288.81kSusan MescoHead of Investor RelationsMr. Richard KahrVice President of Human ResourcesDr. Jonathan Slonin M.D. (Age 49)Chief Medical Officer Comp: $815.25kMore ExecutivesKey CompetitorsOPKO HealthNASDAQ:OPKALX OncologyNASDAQ:ALXOAgios PharmaceuticalsNASDAQ:AGIOAtea PharmaceuticalsNASDAQ:AVIRADC TherapeuticsNYSE:ADCTView All CompetitorsInsiders & InstitutionsBoston PartnersSold 36,748 shares on 5/28/2024Ownership: 0.045%Walleye Trading LLCBought 81,000 shares on 5/17/2024Ownership: 0.000%Janus Henderson Group PLCSold 1,973 shares on 5/16/2024Ownership: 1.293%California State Teachers Retirement SystemSold 2,707 shares on 5/16/2024Ownership: 0.100%Paloma Partners Management CoBought 7,151 shares on 5/16/2024Ownership: 0.015%View All Insider TransactionsView All Institutional Transactions PCRX Stock Analysis - Frequently Asked Questions Should I buy or sell Pacira BioSciences stock right now? 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pacira BioSciences in the last year. There are currently 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PCRX shares. View PCRX analyst ratings or view top-rated stocks. What is Pacira BioSciences' stock price target for 2024? 10 brokers have issued 12 month price objectives for Pacira BioSciences' stock. Their PCRX share price targets range from $38.00 to $57.00. On average, they anticipate the company's share price to reach $47.40 in the next twelve months. This suggests a possible upside of 56.3% from the stock's current price. View analysts price targets for PCRX or view top-rated stocks among Wall Street analysts. How have PCRX shares performed in 2024? Pacira BioSciences' stock was trading at $33.74 on January 1st, 2024. Since then, PCRX stock has decreased by 10.1% and is now trading at $30.33. View the best growth stocks for 2024 here. Are investors shorting Pacira BioSciences? Pacira BioSciences saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 6,040,000 shares, an increase of 67.8% from the April 30th total of 3,600,000 shares. Based on an average daily trading volume, of 643,700 shares, the short-interest ratio is presently 9.4 days. View Pacira BioSciences' Short Interest. When is Pacira BioSciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024. View our PCRX earnings forecast. How were Pacira BioSciences' earnings last quarter? Pacira BioSciences, Inc. (NASDAQ:PCRX) posted its earnings results on Tuesday, May, 7th. The company reported $0.42 EPS for the quarter, missing the consensus estimate of $0.46 by $0.04. The firm had revenue of $167.12 million for the quarter, compared to analysts' expectations of $165.43 million. Pacira BioSciences had a trailing twelve-month return on equity of 12.98% and a net margin of 10.34%. What ETFs hold Pacira BioSciences' stock? ETFs with the largest weight of Pacira BioSciences (NASDAQ:PCRX) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP), SPDR S&P Pharmaceuticals ETF (XPH), Invesco S&P SmallCap Health Care ETF (PSCH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) and ETC 6 Meridian Small Cap Equity ETF (SIXS).iShares U.S. Pharmaceuticals ETF (IHE). What guidance has Pacira BioSciences issued on next quarter's earnings? Pacira BioSciences updated its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $680.0 million-$705.0 million, compared to the consensus revenue estimate of $691.6 million. What is Dave Stack's approval rating as Pacira BioSciences' CEO? 54 employees have rated Pacira BioSciences Chief Executive Officer Dave Stack on Glassdoor.com. Dave Stack has an approval rating of 45% among the company's employees. This puts Dave Stack in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Pacira BioSciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pacira BioSciences investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), Skyworks Solutions (SWKS), AbbVie (ABBV), Pfizer (PFE), QUALCOMM (QCOM), Exelixis (EXEL) and Tesla (TSLA). Who are Pacira BioSciences' major shareholders? Pacira BioSciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (10.99%), Clearbridge Investments LLC (2.52%), Rice Hall James & Associates LLC (2.24%), Baillie Gifford & Co. (2.15%), Janus Henderson Group PLC (1.29%) and Gagnon Securities LLC (1.18%). Insiders that own company stock include Anthony Molloy, Charles A Reinhart III, Charles Anthony Laranjeira, Daryl Gaugler, David M Stack, Donald C Manning, Gary W Pace, John P Phd Longenecker, Jonathan Slonin, Kristen Marie Williams, Lauren Bullaro Riker, Mark A Kronenfeld, Mark Froimson, Max Reinhardt, Paul J Hastings and Roy Winston. View institutional ownership trends. How do I buy shares of Pacira BioSciences? Shares of PCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PCRX) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersBiden Nomination CANCELED?The Freeport SocietyWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pacira BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
